酶
细菌
毒性
药品
微生物学
生物
厌氧菌
药理学
生物化学
化学
遗传学
有机化学
作者
Bret D. Wallace,Hongwei Wang,Kimberly T. Lane,John E. Scott,Jillian Orans,Ja Seol Koo,Madhukumar Venkatesh,Christian Jobin,Li-An Yeh,Sridhar Mani,Matthew R. Redinbo
出处
期刊:Science
[American Association for the Advancement of Science]
日期:2010-11-04
卷期号:330 (6005): 831-835
被引量:1124
标识
DOI:10.1126/science.1191175
摘要
The dose-limiting side effect of the common colon cancer chemotherapeutic CPT-11 is severe diarrhea caused by symbiotic bacterial β-glucuronidases that reactivate the drug in the gut. We sought to target these enzymes without killing the commensal bacteria essential for human health. Potent bacterial β-glucuronidase inhibitors were identified by high-throughput screening and shown to have no effect on the orthologous mammalian enzyme. Crystal structures established that selectivity was based on a loop unique to bacterial β-glucuronidases. Inhibitors were highly effective against the enzyme target in living aerobic and anaerobic bacteria, but did not kill the bacteria or harm mammalian cells. Finally, oral administration of an inhibitor protected mice from CPT-11-induced toxicity. Thus, drugs may be designed to inhibit undesirable enzyme activities in essential microbial symbiotes to enhance chemotherapeutic efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI